featured
Past, Present, and Future of Drug-Eluting Stents
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
- Zotarolimus-Eluting Stents Have Better Outcomes Compared to 1st Generation DES and BMS
- Long-Term Outcome After Drug-Eluting vs Bare-Metal Stent Implantation in Patients With STEMI
- Outcomes With Various Drug-Eluting or Bare Metal Stents in Patients With ST-Segment-Elevation Myocardial Infarction: A Mixed Treatment Comparison Analysis of Trial Level Data From 34,068 Patient-Years of Follow-Up From Randomized Trials
- Highlights of the Year in JACC 2013
-
Tewari K, et al. GOG 240: A Randomized Phase III Trial of Cisplatin Plus Paclitaxel With and Without NCI-Supplied Bevacizumab Versus the Non-Platinum Doublet, Topotecan Plus Paclitaxel, With and Without NCI-Supplied Bevacizumab, In Stage IVB, Recurrent or Persistent Carcinoma of the Cervix. Paper presented at: 44th Annual Meeting of the Society of Gynecologic Oncology; March 9–12, 2013; Los Angeles, CA.